Staging systems for papillary thyroid carcinoma: A study of 2 tertiary referral centers

Annals of Surgery

Volumn 246, Issue 1, 2007, Pages 114-121

  Lang, Brian Hung Hin ^a   Chow, Sin Ming ^b   Lo, Chung Yau ^a,d   Law, Stephen C K ^b   Lam, King Yin ^c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c GRIFFITH UNIVERSITY   (Australia)

^d QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MEDLINE; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REFERRAL AND CONSULTATION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYROID NEOPLASMS; TIME FACTORS; UNITED STATES;

EID: 34347335723     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000262785.46403.9b     Document Type: Article

References (48)

1. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501-511.
2. Cancer incidence and mortality in Hong Kong 1983-2003. Hong Kong Cancer Registry. Available at: http://www.ha.org.hk/cancereg/stat.asp. Accessed May 15, 2006.
3. Haselkorn T, Bernstein L, Preston-Martin S, et al. Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972-1995. Cancer Causes Control. 2000;11:163-170.
4. Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol. 2004;11:1093-1097.
5. Reynolds RM, Weir J, Stockton DL, et al. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf). 2005;62:156-162.
6. Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid. 2006;16:47-53.
7. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1462.
8. Eustatia-Rutten CFA, Corssmit EPM, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:313-319.
9. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma: a study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15:1033-1041.
10. Hay ID, Grant CS, Taylor WF, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088-1095.
11. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947-953.
12. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. Cancer. 1998;83:1012-1021.
13. Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Handbook, 6th ed. New York: Springer-Verlag; 2002.
14. Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope. 2004;114:393-402.
15. Brierley JD, Panzarella T, Tsang RW, et al. A comparison of different staging systems. Predictability of patient outcome: thyroid carcinoma as an example. Cancer. 1997;79:2414-2423.
16. Passler C, Prager G, Scheuba C, et al. Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution. Ann Surg. 2003;207:227-234.
17. Yildirim E. A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. J Am Coll Surg. 2005;200:378-392.
18. Chow SM, Law SC, Au SK, et al. Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute. Head Neck. 2002;24:670-677.
19. Lang BH, Lo CY, Chan WF, et al. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol. 2007;14:730-738.
20. Lorentz TG, Lau PW, Lo CY, et al. Multivariate analysis of risk factors influencing survival in Chinese with papillary thyroid cancer. World J Surg. 1994;18:547-550.
21. DeLellis RA, Lloyd RV, Heitz PU, et al., eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. France: International Agency for Research on Cancer; 2004.
22. Lo CY, Chan WF, Lam KY, et al. Optimizing the treatment of AMES high-risk papillary thyroid carcinoma. World J Surg. 2004;28:1103-1109.
23. Lang BH, Lo CY, Chan WF, et al. Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathological features and long-term outcome. World J Surg. 2006;30:752-758.
24. DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-424.
25. Pasieka JL, Zedenius J, Auer G, et al. Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid carcinoma. Surgery. 1992;112:1154-1160.
26. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-1058.
27. Akslen LA. Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer. 1993;72:2680-2685.
28. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428.
29. Noguchi S, Murakami N, Kawamoto H. Classification of papillary cancer of the thyroid based on prognosis. World J Surg. 1994;18:552-558.
30. Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of the thyroid. Surgery. 1994;116:1036-1041.
31. Lerch H, Schober O, Kuwert T, et al. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol. 1997;15:2067-2075.
32. Beeken S, Roye D, Weiss H, et al. Extent of surgery for intermediate-risk well-differentiated thyroid cancer. Am J Surg. 2000;179:51-56.
33. Ortiz Sebastian S, Rodriguez Gonzalez M, Parilla Paricio P, et al. Papillary thyroid carcinoma: prognostic index for survival including the histological variety. Arch Surg. 2000;135:272-277.
34. Sugitani I, Kasai N, Fujimoto Y, et al. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135:139-148.
35. Schemper M, Stare J. Explained variation in survival analysis. Stat Med. 1996;15:1999-2012.
36. Greene FL. Cancer staging, prognostic factors, and our surgical challenges. Am Surg. 2005;71:615-620.
37. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid carcinoma. Thyroid. 2006;16:109-142.
38. Brierley JD, Catton PA, O'Sullivan B. Accuracy of recorded tumor, node, and metastasis stage in a comprehensive cancer center. J Clin Oncol. 2002;20:413-419.
39. Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin. 2005;55:242-258.
40. Sherman SI. Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. Semin Surg Oncol. 1999;16:12-15.
41. 131I ablation as an alternative to completion/total thyroidectomy in the treatment of well-differentiated thyroid cancer. Surgery. 2004;136:1275-1280.
42. Goropoulos A, Karamoshos K, Christodoulou A, et al. Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma. World J Surg. 2004;28:1275-1281.
43. Pereira JA, Jimeno J, Miquel J, et al. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery. 2005;138:1095-1101.
44. Au SK, Law CK, Foo W, et al. In-depth evaluation of the AJCC/UICC 1997 staging system of nasopharyngeal carcinoma: prognostic homogeneity and proposed refinements. Int J Radiat Oncol Biol Phys. 2003;56:413-426.
45. D'Avanzo A, Ituarte P, Treseler P, et al. Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid. 2004;14:453-458.
46. Lo CY, Chan WF, Lam KY, et al. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. Ann Surg. 2005;242:708-715.
47. Barbet J, Campion L, Kraeber-Bodere F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077-6084.
48. Boulos DL, Groome PA, Brundage MD, et al. Predictive validity of five comorbidity indices in prostate carcinoma patients with curative intent. Cancer. 2006;106:1804-1814.